Adams Street Partners LLC purchased $4.8M worth of shares in Aptinyx, Inc. in June 2018
Jul 08, 2018
Aptinyx Inc. is a clinical stage biopharmaceutical company. It engages in the discovery, development, and and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G. Riedel and Joseph R. Moskal in June 2015 and is headquartered in Evanston, IL.
In The News
Aptinyx Presents Data Demonstrating Positive Activity of NYX-458 on Cognitive Performance and Biomarkers in a Preclinical Model of Head Injury
Aug 21, 2019 - GlobeNewswire
Aug 12, 2019 - SEC
Aug 12, 2019 - GlobeNewswire
Adams Street Partners is one of the leading independent, employee-owned firms that specializing in direct, primary & secondary investments and also considers co-investment opportunities. For direct investments, the firm focuses on technology (software, mobile, big data, financial technology, security) and healthcare sectors. They partner with exceptional teams and invest at various stages of a company's life-cycle. They make investments in the range of $5 million to $25 million and invest more, depending on the situation. For primary fund of fund investments, the firm invests globally in private equity funds, regardless of geography, stage or subclass. They make secondary investments through dedicated stand-alone secondary funds as well as fund-of-funds. The firm also co-invests alongside other general partners in buyout and growth equity investments in small and medium sized companies.
In The News
TurnKey Vacation Rentals Raises $48 Million in New Funding Round, Surpassing $100 Million in Total Funding Since 2013
Jul 23, 2019 - PR Newswire
Jun 18, 2019 - peHUB
May 30, 2019 - SNL Financial